Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Diabetes Mellitus HELP
Based on 100,000 articles published since 2008
|||| 38 

These are the 100000 published articles about Diabetes Mellitus that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline 2019 Canadian guideline for physical activity throughout pregnancy. 2018

Mottola, Michelle F / Davenport, Margie H / Ruchat, Stephanie-May / Davies, Gregory A / Poitras, Veronica J / Gray, Casey E / Jaramillo Garcia, Alejandra / Barrowman, Nick / Adamo, Kristi B / Duggan, Mary / Barakat, Ruben / Chilibeck, Phil / Fleming, Karen / Forte, Milena / Korolnek, Jillian / Nagpal, Taniya / Slater, Linda G / Stirling, Deanna / Zehr, Lori. ·R Samuel McLaughlin Foundation-Exercise and Pregnancy Laboratory, School of Kinesiology, Faculty of Health Sciences, Department of Anatomy and Cell Biology, Schulich School of Medicine & Dentistry, Children's Health Research Institute, The University of Western Ontario, London, Ontario, Canada. · Program for Pregnancy and Postpartum Health, Faculty of Kinesiology, Sport and Recreation, Women and Children's Health Research Institute, Alberta Diabetes Institute, University of Alberta, Edmonton, Alberta, Canada. · Department of Human Kinetics, Universite du Quebec a Trois-Rivieres, Trois-Rivieres, Quebec, Canada. · Department of Obstetrics and Gynecology, Queen's University, Kingston, Ontario, Canada. · Independent Researcher, Ottawa, Ontario, Canada. · Healthy Active Living and Obesity Research Group, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. · Clinical Research Unit, Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada. · School of Human Kinetics, Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada. · Canadian Society for Exercise Physiology, Ottawa, Ontario, Canada. · Facultad de Ciencias de la Actividad Física y del Deporte-INEF, Universidad Politécnica de Madrid, Madrid, Spain. · College of Kinesiology, University of Saskatchewan, Saskatoon, Canada. · Department of Family and Community Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. · Department of Family and Community Medicine, University of Toronto, Granovsky Gluskin Family Medicine Centre, Sinai Health System, Sinai Health System, Toronto, Ontario, Canada. · Canadian Association of Midwives, Toronto, Canada. · John W Scott Health Sciences Library, University of Alberta, Edmonton, Alberta, Canada. · Middlesex-London Health Unit, London, Ontario, Canada. · School of Health and Human Services, Camosun College, Victoria, Canada. ·Br J Sports Med · Pubmed #30337460.

ABSTRACT: The objective is to provide guidance for pregnant women and obstetric care and exercise professionals on prenatal physical activity. The outcomes evaluated were maternal, fetal or neonatal morbidity, or fetal mortality during and following pregnancy. Literature was retrieved through searches of MEDLINE, EMBASE, PsycINFO, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, Scopus and Web of Science Core Collection, CINAHL Plus with Full Text, Child Development & Adolescent Studies, Education Resources Information Center, SPORTDiscus, ClinicalTrials.gov and the Trip Database from inception up to 6 January 2017. Primary studies of any design were eligible, except case studies. Results were limited to English-language, Spanish-language or French-language materials. Articles related to maternal physical activity during pregnancy reporting on maternal, fetal or neonatal morbidity, or fetal mortality were eligible for inclusion. The quality of evidence was rated using the Grading of Recommendations Assessment, Development and Evaluation methodology. The Guidelines Consensus Panel solicited feedback from end users (obstetric care providers, exercise professionals, researchers, policy organisations, and pregnant and postpartum women). The development of these guidelines followed the Appraisal of Guidelines for Research and Evaluation II instrument. The benefits of prenatal physical activity are moderate and no harms were identified; therefore, the difference between desirable and undesirable consequences (net benefit) is expected to be moderate. The majority of stakeholders and end users indicated that following these recommendations would be feasible, acceptable and equitable. Following these recommendations is likely to require minimal resources from both individual and health systems perspectives.

2 Guideline Behavioral Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: US Preventive Services Task Force Recommendation Statement. 2018

Anonymous6900965 / Curry, Susan J / Krist, Alex H / Owens, Douglas K / Barry, Michael J / Caughey, Aaron B / Davidson, Karina W / Doubeni, Chyke A / Epling, John W / Grossman, David C / Kemper, Alex R / Kubik, Martha / Landefeld, C Seth / Mangione, Carol M / Phipps, Maureen G / Silverstein, Michael / Simon, Melissa A / Tseng, Chien-Wen / Wong, John B. ·University of Iowa, Iowa City. · Fairfax Family Practice Residency, Fairfax, Virginia. · Virginia Commonwealth University, Richmond. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California. · Stanford University, Stanford, California. · Harvard Medical School, Boston, Massachusetts. · Oregon Health & Science University, Portland. · Columbia University, New York, New York. · University of Pennsylvania, Philadelphia. · Virginia Tech Carilion School of Medicine, Roanoke. · Kaiser Permanente Washington Health Research Institute, Seattle. · Nationwide Children's Hospital, Columbus, Ohio. · Temple University, Philadelphia, Pennsylvania. · University of Alabama at Birmingham. · University of California, Los Angeles. · Brown University, Providence, Rhode Island. · Boston University, Boston, Massachusetts. · Northwestern University, Evanston, Illinois. · University of Hawaii, Honolulu. · Pacific Health Research and Education Institute, Honolulu, Hawaii. · Tufts University, Medford, Massachusetts. ·JAMA · Pubmed #30326502.

ABSTRACT: Importance: More than 35% of men and 40% of women in the United States are obese. Obesity is associated with health problems such as increased risk for coronary heart disease, type 2 diabetes, various types of cancer, gallstones, and disability. Obesity is also associated with an increased risk for death, particularly among adults younger than 65 years. Objective: To update the US Preventive Services Task Force (USPSTF) 2012 recommendation on screening for obesity in adults. Evidence Review: The USPSTF reviewed the evidence on interventions (behavioral and pharmacotherapy) for weight loss or weight loss maintenance that can be provided in or referred from a primary care setting. Surgical weight loss interventions and nonsurgical weight loss devices (eg, gastric balloons) are considered to be outside the scope of the primary care setting. Findings: The USPSTF found adequate evidence that intensive, multicomponent behavioral interventions in adults with obesity can lead to clinically significant improvements in weight status and reduce the incidence of type 2 diabetes among adults with obesity and elevated plasma glucose levels; these interventions are of moderate benefit. The USPSTF found adequate evidence that behavior-based weight loss maintenance interventions are of moderate benefit. The USPSTF found adequate evidence that the harms of intensive, multicomponent behavioral interventions (including weight loss maintenance interventions) in adults with obesity are small to none. Therefore, the USPSTF concludes with moderate certainty that offering or referring adults with obesity to intensive behavioral interventions or behavior-based weight loss maintenance interventions has a moderate net benefit. Conclusions and Recommendation: The USPSTF recommends that clinicians offer or refer adults with a body mass index of 30 or higher to intensive, multicomponent behavioral interventions. (B recommendation).

3 Guideline Glycaemic management during the inpatient enteral feeding of people with stroke and diabetes. 2018

Roberts, A W / Penfold, S / Anonymous3251013. ·Cardiff and Vale University Health Board, Cardiff, UK. · Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Bournemouth, UK. ·Diabet Med · Pubmed #30152589.

ABSTRACT: This paper is an abridged and modified version of guidelines produced by the Joint British Diabetes Societies for inpatient care on glycaemic management during the enteral feeding of people with stroke and diabetes. These were revised in 2017 and have been adapted specifically for Diabetic Medicine. The full version can be found at: www.diabetes.org.uk/joint-british-diabetes-society or https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group. Many people have both diabetes and an acute stroke, and a stanv dard approach to the management of people with stroke is the provision of adequate nutrition. Frequently, this involves a period of enteral feeding if there is impaired ability to swallow food safely. There is currently considerable variability in the management of people with diabetes fed enterally after a stroke, and the evidence base guiding diabetes management in this clinical situation is very weak, although poor glycaemic outcomes in people receiving enteral feeding after stroke may worsen recovery and cause harm. The aim of this document is to provide sensible clinical guidance in this area, written by a multidisciplinary team; this guideline had input from diabetes specialist nurses, diabetologists, dietitians, stroke physicians and pharmacists with expertise in this area, and from UK professional organizations. It is aimed at multidisciplinary teams managing people with stroke and diabetes who require enteral feeding. We recognize that there is limited clinical evidence in this area.

4 Guideline Managing hyperglycaemia during antenatal steroid administration, labour and birth in pregnant women with diabetes. 2018

Dashora, U / Murphy, H R / Temple, R C / Stanley, K P / Castro, E / George, S / Dhatariya, K / Haq, M / Sampson, M / Anonymous3241013. ·Conquest Hospital, St Leonards on Sea, UK. · Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. · Norwich Medical School, University of East Anglia, Norwich, UK. · Norfolk and Norwich University Hospital, Norwich, UK. · East Sussex Healthcare NHS Trust, St Leonards on Sea, UK. · East and North Hertfordshire NHS Trust, Stevenage, UK. · Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, UK. ·Diabet Med · Pubmed #30152588.

ABSTRACT: Optimal glycaemic control before and during pregnancy improves both maternal and fetal outcomes. This article summarizes the recently published guidelines on the management of glycaemic control in pregnant women with diabetes on obstetric wards and delivery units produced by the Joint British Diabetes Societies for Inpatient Care and available in full at www.diabetes.org.uk/joint-british-diabetes-society and https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group. Hyperglycaemia following steroid administration can be managed by variable rate intravenous insulin infusion (VRIII) or continuous subcutaneous insulin infusion (CSII) in women who are willing and able to safely self-manage insulin dose adjustment. All women with diabetes should have capillary blood glucose (CBG) measured hourly once they are in established labour. Those who are found to be higher than 7 mmol/l on two consecutive occasions should be started on VRIII. If general anaesthesia is used, CBG should be monitored every 30 min in the theatre. Both the VRIII and CSII rate should be reduced by at least 50% once the placenta is delivered. The insulin dose needed after delivery in insulin-treated Type 2 and Type 1 diabetes is usually 25% less than the doses needed at the end of first trimester. Additional snacks may be needed after delivery especially if breastfeeding. Stop all anti-diabetes medications after delivery in gestational diabetes. Continue to monitor CBG before and 1 h after meals for up to 24 h after delivery to pick up any pre-existing diabetes or new-onset diabetes in pregnancy. Women with Type 2 diabetes on oral treatment can continue to take metformin after birth.

5 Guideline Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. 2018

Roberts, A / James, J / Dhatariya, K / Anonymous3221013. ·Cardiff and Vale University Local Health Board, Cardiff, UK. · University Hospitals Leicester NHS Trust, Leicester, UK. · Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK. ·Diabet Med · Pubmed #30152586.

ABSTRACT: Glucocorticoids (steroids) are widely used across many medical specialities for their anti-inflammatory and immunosuppressive properties. However, one of their major side effects is the development of hyperglycaemia. It is well recognized that high glucose levels in people with diabetes in hospital are associated with harm and increased lengths of hospital stay. The use of glucocorticoid (steroid) treatment in people with pre-existing diabetes will undoubtedly result in worsening glucose control, and this may be termed 'steroid-induced hyperglycaemia', and will warrant temporary additional, and more active, glycaemic management. A rise in glucose may occur in people without a known diagnosis of diabetes, and this may be termed 'steroid-induced diabetes'. There is a lack of evidence to guide how people with hyperglycaemia should be managed, and much of the guidance given here is a consensus based on best practice collated from around the United Kingdom. Where evidence is available, this is referenced. These guidelines on the management of people with diabetes treated with steroids has been adapted specifically for Diabetic Medicine. The full version of the guidelines can be found on line at: www.diabetes.org.uk/joint-british-diabetes-society or https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group.

6 Guideline Management of adults with diabetes on the haemodialysis unit: summary of guidance from the Joint British Diabetes Societies and the Renal Association. 2018

Frankel, A H / Kazempour-Ardebili, S / Bedi, R / Chowdhury, T A / De, P / El-Sherbini, Nevine / Game, F / Gray, S / Hardy, D / James, J / Kong, M-F / Ramlan, G / Southcott, E / Winocour, P. ·Imperial College Healthcare NHS Trust, London, UK. · Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Iran. · Royal London Hospital, Whitechapel, London, UK. · Birmingham City Hospital (Sandwell and West Birmingham Hospitals NHS Trust), Birmingham, UK. · Derby Teaching Hospitals NHS Foundation Trust and University of Nottingham, UK. · East and North Herts NHS Trust, UK. · University Hospitals of Leicester NHS Trust, UK. · North Middlesex University Hospital NHS Trust, UK. · St James University Hospital, Leeds, UK. · Queen Elizabeth II Hospital, Welwyn Garden City, UK. ·Diabet Med · Pubmed #30152585.

ABSTRACT: Diabetic nephropathy remains the principal cause of end-stage renal failure in the UK and its prevalence is set to increase. People with diabetes and end-stage renal failure on maintenance haemodialysis are highly vulnerable, with complex comorbidities, and are at high risk of adverse cardiovascular outcomes, the leading cause of mortality in this population. The management of people with diabetes receiving maintenance haemodialysis is shared between diabetes and renal specialist teams and the primary care team, with input from additional healthcare professionals providing foot care, dietary support and other aspects of multidisciplinary care. In this setting, one specialty may assume that key aspects of care are being provided elsewhere, which can lead to important components of care being overlooked. People with diabetes and end-stage renal failure require improved delivery of care to overcome organizational difficulties and barriers to communication between healthcare teams. No comprehensive guidance on the management of this population has previously been produced. These national guidelines, the first in this area, bring together in one document the disparate needs of people with diabetes on maintenance haemodialysis. The guidelines are based on the best available evidence, or on expert opinion where there is no clear evidence to inform practice. We aim to provide clear advice to clinicians caring for this vulnerable population and to encourage and improve education for clinicians and people with diabetes to promote empowerment and self-management.

7 Guideline Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS): guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings. 2018

Price, H C / Ismail, K / Anonymous3211013. ·Southern Health NHS Foundation Trust, Southampton, UK. · Department of Psychological Medicine, Institute of Psychiatry, King's College London, London, UK. ·Diabet Med · Pubmed #30152583.

ABSTRACT: The Royal College of Psychiatrists Liaison Faculty & Joint British Diabetes Societies (JBDS) for Inpatient Care guidelines for the management of diabetes in adults and children with psychiatric disorders in inpatient settings are available in full at: www.diabetes.org.uk/joint-british-diabetes-society and https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group. This article summarizes the guidelines and recommendations. Commissioners are urged to ensure that the needs of people with diabetes and severe mental illness are specifically addressed in contracts with providers of inpatient care, and to avoid financial or other barriers to cross-organizational working and to ensure that patient-structured education is commissioned to meets the complex needs of people with diabetes and severe mental illness. Acute trusts are asked to develop joint pathways with mental health providers and facilitate multidisciplinary working and to screen for mental ill health in those admitted with acute complications of diabetes whose aetiology is unclear or not medically explained. Mental health trusts should create a diabetes register, screen for diabetes, particularly in those prescribed second-generation antipsychotics and ensure that staff are trained in managing and avoiding hypoglycaemia, and the safe use of insulin. Finally, clinical teams should ensure that all staff can access training in diabetes and mental health to support them to care for people with both diabetes and severe mental illness, develop local pathways for joint working and ensure best practice tariff criteria are met for diabetic ketoacidosis and hypoglycaemia, and for children and young people with diabetes.

8 Guideline Updates to the 2018

Anonymous4960959. · ·Diabetes Care · Pubmed #30135199.

ABSTRACT: -- No abstract --

9 Guideline Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. 2018

Chiang, Jane L / Maahs, David M / Garvey, Katharine C / Hood, Korey K / Laffel, Lori M / Weinzimer, Stuart A / Wolfsdorf, Joseph I / Schatz, Desmond. ·McKinsey & Company and Diasome Pharmaceuticals, Inc., Palo Alto, CA. · Department of Pediatrics, Stanford University School of Medicine, Stanford, CA. · Division of Endocrinology, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA. · Joslin Diabetes Center, Harvard Medical School, Boston, MA. · Pediatric Endocrinology & Diabetes, Yale School of Medicine, New Haven, CT. · Division of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL schatz@ufl.edu. ·Diabetes Care · Pubmed #30093549.

ABSTRACT: -- No abstract --

10 Guideline Consensus document of the Spanish Society of Arteriosclerosis (SEA) for the prevention and treatment of cardiovascular disease in type 2 diabetes mellitus. 2018

Ruiz-García, Antonio / Arranz-Martínez, Ezequiel / Morón-Merchante, Ignacio / Pascual-Fuster, Vicente / Tamarit, Juan J / Trias-Villagut, Ferran / Pintó-Sala, Xavier / Ascaso, Juan F / Anonymous3610974. ·Centro de Salud Universitario Pinto, Unidad de Lípidos y Prevención Cardiovascular, Universidad Europea de Madrid, Pinto, Madrid, España. · Centro de Salud San Blas, Parla, Madrid, España. · Centro de Salud Universitario Goya, Universidad Autónoma de Madrid, Madrid, España. · Centro de Salud Palleter, Universidad CEU-Cardenal Herrera, Castellón, España. Electronic address: pascual_vic@gva.es. · Consorcio Hospital General Universitario, Valencia, España. · Hospital de Bellvitge, Universitat de Barcelona, Barcelona, España. · Hospital Clínico-Universitat de València, INCLIVA Research Institute, CIBER de Diabetes y Enfermedades Metabólicas (CIBERDEM), ISCIII, Valencia, España. ·Clin Investig Arterioscler · Pubmed #30053980.

ABSTRACT: A consensus document of the Diabetes working group of the Spanish Society of Arteriosclerosis (SEA) is presented, based on the latest studies and conceptual changes that have appeared. It presents the cardiovascular risk in type 2 diabetes mellitus (T2DM) and the action guidelines for the prevention and treatment of cardiovascular disease (CVD) associated with T2DM. The importance of lipid control, based on the objective of LDL-C and non-HDL-C when there is hypertriglyceridemia, and the blood pressure control in the prevention and treatment of CVD is evaluated. The new hypoglycemic drugs and their effects on CVD are reviewed, as well as the treatment and control guidelines of hyperglycemia. Likewise, the use of antiplatelet agents is considered. Emphasis is placed on the importance of global and simultaneous action on all risk factors to achieve a significant reduction in cardiovascular events. This supplement is sponsored by Laboratorios Esteve, S.A.

11 Guideline Practical Recommendations for Glucose Measurement, Glucose Monitoring and Glucose Control in Patients with Type 1 or Type 2 Diabetes in Germany. 2018

Heinemann, Lutz / Deiss, Dorothee / Siegmund, Thorsten / Schlüter, Sandra / Naudorf, Michael / von Sengbusch, Simone / Lange, Karin / Freckmann, Guido. ·Arbeitsgemeinschaft Diabetes & Technologie der Deutschen Diabetes Gesellschaft e.V., Ulm (Diabetes & Technology Working Group of the German Diabetes Association). · Arbeitsgemeinschaft für Pädiatrische Diabetologie e. V., Münster (Paediatric Diabetology Working Group). ·Exp Clin Endocrinol Diabetes · Pubmed #29975980.

ABSTRACT: -- No abstract --

12 Guideline Definition, Classification and Diagnosis of Diabetes Mellitus. 2018

Petersmann, Astrid / Nauck, Matthias / Müller-Wieland, Dirk / Kerner, Wolfgang / Müller, Ulrich A / Landgraf, Rüdiger / Freckmann, Guido / Heinemann, Lutz. ·Kommission für Labordiagnostik der Diabetologie der Deutschen Diabetes Gesellschaft (DDG) und der Deutschen Gesellschaft für Klinische Chemie und Laboratoriumsmedizin (DGKL) (Commission for Laboratory Diagnostics in Diabetology of the German Diabetes Association (DDG) and the German Association for Clinical Chemistry and Laboratory Medicine). ·Exp Clin Endocrinol Diabetes · Pubmed #29975979.

ABSTRACT: Aim of recommendations like this one issued by the German Diabetes Association is to provide the GP and diabetologist and his team with information he needs for his daily practice. These recommendations are updated annually. They are written by a group of experts, but they are not evidence based guidelines. This specific recommendation for diabetes diagnosis briefly describes the diabetes types and the different options for diagnosis. Also the caveats and the practical procedure are presented.

13 Guideline Self-management of diabetes in hospital: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. 2018

Flanagan, D / Dhatariya, K / Kilvert, A / Anonymous2961013. ·Plymouth Hospitals NHS Trust, Plymouth. · Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK. · Northampton General Hospital NHS Trust, Northampton, UK. ·Diabet Med · Pubmed #29923215.

ABSTRACT: The aims of these guidelines are to improve the inpatient experience and safety for people with diabetes through effective self-management. The guidelines are aimed primarily at healthcare professionals working in hospitals, although some aspects are relevant to staff involved in pre-admission preparation. The guidelines suggest an approach to providing patient information, the circumstances in which self-management is appropriate, the development of care plans and the elements needed for effective self-management. This document is an abridged and modified version of 'Self-management of diabetes in hospital' adapted specifically for Diabetic Medicine. The full version can be found online at: www.diabetes.org.uk/joint-british-diabetes-society or https://abcd.care/joint-british-diabetes-societies-jbds-inpatient-care-group.

14 Guideline Diabetes mellitus and cardiovascular risk: Update of the recommendations of the Diabetes and Cardiovascular Disease working group of the Spanish Diabetes Society (SED, 2018). 2018

Arrieta, Francisco / Iglesias, Pedro / Pedro-Botet, Juan / Becerra, Antonio / Ortega, Emilio / Obaya, Juan Carlos / Nubiola, Andreu / Maldonado, Gonzalo Fernando / Campos, Maria Del Mar / Petrecca, Romina / Pardo, José Luis / Sánchez-Margalet, Víctor / Alemán, José Juan / Navarro, Jorge / Duran, Santiago / Tébar, Francisco Javier / Aguilar, Manuel / Escobar, Fernando / Anonymous200947. ·Hospital Universitario Ramón y Cajal, CIBEROBN, IRYCIS, Madrid, España. Electronic address: arri68@hotmail.com. · Hospital Universitario Puerta de Hierro-Mjadahonda, Madrid, España. · Parc de Salut Mar, Barcelona, España. · Hospital Universitario Ramón y Cajal, Madrid, España. · Hospital Universitario Araba, Vitoria-Gasteiz, España. · Hospital Clínic i Universitari, CIBEROBN, IDIBAPS, Barcelona, España. · Centro de Salud Chopera, Alcobendas, Madrid, España. · Hospital de l'Esperit Sant, Santa Coloma de Gramenet, Barcelona, España. · Hospital Universitario San Cecilio, Granada, España. · Hospital Universitario Princesa, Madrid, España. · Centro de Salud Orihuela, Orihuela, Alicante, España. · Hospital Universitario Virgen Macarena, Sevilla, España. · Centro de Salud Tacoronte, Tacoronte, Santa Cruz de Tenerife, España. · Hospital Universitario Nuestra Señora de Valme, Sevilla, España. · Dirección de Atención Primaria, IIS INCLIVA, CIBERESP, Valencia, España. · Hospital Universitario Virgen de la Arrixaca, Murcia, España. · Hospital Puerta del Mar, Cádiz, España. ·Clin Investig Arterioscler · Pubmed #29754804.

ABSTRACT: This document is an update to the clinical practice recommendations for the management of cardiovascular risk factors in diabetes mellitus. The consensus is made by members of the Cardiovascular Risk Group of the Spanish Diabetes Society. We have proposed and updated interventions on lifestyle, pharmacological treatment indicated to achieve therapeutic objectives according to the levels of HbA1c, degree of obesity, hypertension, hyperlipidemia, heart failure, platelet antiagregation, renal insufficiency, and diabetes in the elderly, as well as new biomarkers of interest in the evaluation of cardiovascular risk in individuals with diabetes mellitus. The work is an update of the interventions and therapeutic objectives in addition, it is noted the need for the inclusion of specialists in Endocrinology, Metabolism and Nutrition in Cardiac Rehabilitation Units for the control and monitoring of this population.

15 Guideline Insulin Access and Affordability Working Group: Conclusions and Recommendations. 2018

Cefalu, William T / Dawes, Daniel E / Gavlak, Gina / Goldman, Dana / Herman, William H / Van Nuys, Karen / Powers, Alvin C / Taylor, Simeon I / Yatvin, Alan L / Anonymous4010946. ·American Diabetes Association, Arlington, VA wcefalu@diabetes.org. · Morehouse School of Medicine, Atlanta, GA. · North Coast Health, Lakewood, OH. · USC Schaeffer Center for Health Policy & Economics, Los Angeles, CA. · University of Michigan, Ann Arbor, MI. · Vanderbilt University Medical Center, Nashville, TN. · University of Maryland School of Medicine, Baltimore, MD. · Popper & Yatvin, Philadelphia, PA. ·Diabetes Care · Pubmed #29739814.

ABSTRACT: -- No abstract --

16 Guideline The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help? 2018

Ceriello, Antonio / Gavin, James R / Boulton, Andrew J M / Blickstead, Rick / McGill, Margaret / Raz, Itamar / Sadikot, Shaukat / Wood, David A / Cos, Xavier / Khunti, Kamlesh / Kalra, Sanjay / Das, Ashok Kumar / López, Cutberto Espinosa / Anonymous12590941. ·Department of Cardiovascular and Metabolic Diseases, IRCCS Multimedica, Milan, Italy; Insititut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. Electronic address: aceriell@clinic.ub.es. · Emory University School of Medicine, Atlanta, GA, USA. · Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. · Diabetes Canada, Toronto, Canada. · Central Clinical School, The University of Sydney, Sydney, Australia; The Diabetes Centre, Royal Prince Alfred Hospital, Sydney, Australia. · Hadassah Ein Kerem Hospital, Jerusalem, Israel. · Department of Endocrinology/Diabetology, Jaslok Hospital and Research Centre, Mumbai, India. · International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, UK. · Sant Marti de Provençals Primary Care Centres, Institut Català de la Salut, Barcelona, Spain; University Research Institute in Primary Care (IDIAP Jordi Gol), Barcelona, Spain. · Diabetes Research Centre, University of Leicester, Leicester, United Kingdom. · Bharti Hospital and B.R.I.D.E., Karnal, India. · Pondicherry Institute of Medical Sciences, Pondicherry, Puducherry, India. · CENAPRECE "National Center for Preventive Programs and Disease Control", Mexico City, Mexico. ·Diabetes Res Clin Pract · Pubmed #29596943.

ABSTRACT: Diabetes is a major global epidemic and places a huge burden on healthcare systems worldwide. The complications of type 2 diabetes (T2D) and related hospitalizations are major contributors to this burden, and there is strong evidence that the risk for these can be reduced by early action to identify and prevent progression of people at high risk of T2D and ensure tight glycemic control in those with established disease. In response to this, the Berlin Declaration was developed by four working groups of experts and ratified by healthcare professionals from 38 countries. Its aim is to act as a global call to action for early intervention in diabetes, in addition to providing short-, medium- and long-term targets that should be relevant to all nations. The Berlin Declaration focuses on four aspects of early action, and proposes actionable policies relating to each aspect: early detection, prevention, early control and early access to the right interventions. In addition, a number of treatment targets are proposed to provide goals for these policies. To ensure that the suggested policies are enacted in the most effective manner, the support of specialist care professionals is considered essential.

17 Guideline AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. 2018

Grunberger, George / Handelsman, Yehuda / Bloomgarden, Zachary T / Fonseca, Vivian A / Garber, Alan J / Haas, Richard A / Roberts, Victor L / Umpierrez, Guillermo E. · ·Endocr Pract · Pubmed #29547046.

ABSTRACT: This document represents the official position of the American Association of Clinical Endocrinologists and American College of Endocrinology. Where there are no randomized controlled trials or specific U.S. FDA labeling for issues in clinical practice, the participating clinical experts utilized their judgment and experience. Every effort was made to achieve consensus among the committee members. Position statements are meant to provide guidance, but they are not to be considered prescriptive for any individual patient and cannot replace the judgment of a clinician. AACE/ACE Task Force on Integration of Insulin Pumps and Continuous Glucose Monitoring in the Management of Patients With Diabetes Mellitus Chair George Grunberger, MD, FACP, FACE Task Force Members Yehuda Handelsman, MD, FACP, FNLA, MACE Zachary T. Bloomgarden, MD, MACE Vivian A. Fonseca, MD, FACE Alan J. Garber, MD, PhD, FACE Richard A. Haas, MD, FACE Victor L. Roberts, MD, MBA, FACP, FACE Guillermo E. Umpierrez, MD, CDE, FACP, FACE Abbreviations: AACE = American Association of Clinical Endocrinologists ACE = American College of Endocrinology A1C = glycated hemoglobin BGM = blood glucose monitoring CGM = continuous glucose monitoring CSII = continuous subcutaneous insulin infusion DM = diabetes mellitus FDA = Food & Drug Administration MDI = multiple daily injections T1DM = type 1 diabetes mellitus T2DM = type 2 diabetes mellitus SAP = sensor-augmented pump SMBG = self-monitoring of blood glucose STAR 3 = Sensor-Augmented Pump Therapy for A1C Reduction phase 3 trial.

18 Guideline Practical management of diabetes patients before, during and after surgery: A joint French diabetology and anaesthesiology position statement. 2018

Cosson, E / Catargi, B / Cheisson, G / Jacqueminet, S / Ichai, C / Leguerrier, A-M / Ouattara, A / Tauveron, I / Bismuth, E / Benhamou, D / Valensi, P. ·Département d'endocrinologie-diabétologie-nutrition, CRNH-IdF, CINFO, hôpital Jean-Verdier, université Paris 13, Sorbonne Paris Cité, AP-HP, 93140 Bondy, France; UMR U1153 Inserm, U1125 Inra, CNAM, université Paris 13, Sorbonne Paris Cité, 93000 Bobigny, France. · Service d'endocrinologie-maladies métaboliques, hôpital Saint-André, CHU de Bordeaux, 1, rue Jean-Burguet, 33000 Bordeaux, France. Electronic address: bogdan.catargi@chu-bordeaux.fr. · Service d'anesthésie-réanimation chirurgicale, hôpitaux universitaires Paris-Sud, hôpital de Bicêtre, AP-HP, 78, rue du Général-Leclerc, 94275 Le Kremlin-Bicêtre, France. · Institut de cardio-métabolisme et nutrition, hôpital de la Pitié-Salpêtrière, AP-HP, 75013 Paris, France; Département du diabète et des maladies métaboliques, hôpital de la Pitié-Salpêtrière, 75013 Paris, France. · Service de la réanimation polyvalente, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06001 Nice cedex 1, France; IRCAN, Inserm U1081, CNRS UMR 7284, university hospital of Nice, 06000 Nice, France. · Service de diabétologie-endocrinologie, CHU hôpital Sud, CHU de Rennes, 16, boulevard de Bulgarie, 35056 Rennes, France. · Department of anaesthesia and critical care II, Magellan medico-surgical center, CHU de Bordeaux, 33000 Bordeaux, France; Inserm, UMR 1034, biology of cardiovascular diseases, université Bordeaux, 33600 Pessac, France. · Service d'endocrinologie-diabétologie, CHU de Clermont-Ferrand, 58, rue Montalembert, 63000 Clermont-Ferrand, France; UFR médecine, université Clermont-Auvergne, 28, place Henri-Dunant, 63000 Clermont-Ferrand, France; UMR CNRS 6293, Inserm U1103, génétique reproduction et développement, université Clermont-Auvergne, 63170 Aubière, France; Endocrinologie-diabétologie, CHU G.-Montpied, BP 69, 63003 Clermont-Ferrand, France. · Service d'endocrinologie-pédiatrie-diabète, hôpital Robert-Debré, AP-HP, 75019 Paris, France. · Département d'endocrinologie-diabétologie-nutrition, CRNH-IdF, CINFO, hôpital Jean-Verdier, université Paris 13, Sorbonne Paris Cité, AP-HP, 93140 Bondy, France. ·Diabetes Metab · Pubmed #29496345.

ABSTRACT: -- No abstract --

19 Guideline Diabetes UK evidence-based nutrition guidelines for the prevention and management of diabetes. 2018

Dyson, P A / Twenefour, D / Breen, C / Duncan, A / Elvin, E / Goff, L / Hill, A / Kalsi, P / Marsland, N / McArdle, P / Mellor, D / Oliver, L / Watson, K. ·OCDEM, University of Oxford, Oxford, UK. · Diabetes UK - Clinical Care, London, UK. · School of Medicine, University College Dublin, Dublin, UK. · Nutrition and Dietetics, Guys and St Thomas' NHS Foundation Trust, London, UK. · Division of Diabetes and Nutritional Sciences, King's College London, London, UK. · NICHE, University of Ulster, Coleraine, Londonderry, UK. · Community Nutrition, Birmingham Community Healthcare NHS Trust, Birmingham, UK. · School of Life Sciences, University of Canberra, Canberra, Australia. · Nutrition and Dietetics, North Tyneside General Hospital North Shields, Tyne and Wear, London, UK. · Nutrition and Dietetics, King's College Hospital NHS Foundation Trust, London, UK. ·Diabet Med · Pubmed #29443421.

ABSTRACT: A summary of the latest evidence-based nutrition guidelines for the prevention and management of diabetes is presented. These guidelines are based on existing recommendations last published in 2011, and were formulated by an expert panel of specialist dietitians after a literature review of recent evidence. Recommendations have been made in terms of foods rather than nutrients wherever possible. Guidelines for education and care delivery, prevention of Type 2 diabetes, glycaemic control for Type 1 and Type 2 diabetes, cardiovascular disease risk management, management of diabetes-related complications, other considerations including comorbidities, nutrition support, pregnancy and lactation, eating disorders, micronutrients, food supplements, functional foods, commercial diabetic foods and nutritive and non-nutritive sweeteners are included. The sections on pregnancy and prevention of Type 2 diabetes have been enlarged and the weight management section modified to include considerations of remission of Type 2 diabetes. A section evaluating detailed considerations in ethnic minorities has been included as a new topic. The guidelines were graded using adapted 'GRADE' methodology and, where strong evidence was lacking, grading was not allocated. These 2018 guidelines emphasize a flexible, individualized approach to diabetes management and weight loss and highlight the emerging evidence for remission of Type 2 diabetes. The full guideline document is available at www.diabetes.org.uk/nutrition-guidelines.

20 Guideline SMFM Statement: Pharmacological treatment of gestational diabetes. 2018

Anonymous6800935. ·Society for Maternal-Fetal Medicine, Washington, DC. ·Am J Obstet Gynecol · Pubmed #29409848.

ABSTRACT: -- No abstract --

21 Guideline Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations. 2018

Martini, Daniela / Biasini, Beatrice / Zavaroni, Ivana / Bedogni, Giorgio / Musci, Marilena / Pruneti, Carlo / Passeri, Giovanni / Ventura, Marco / Galli, Daniela / Mirandola, Prisco / Vitale, Marco / Dei Cas, Alessandra / Bonadonna, Riccardo C / Del Rio, Daniele. ·The Laboratory of Phytochemicals in Physiology, Department of Food and Drug, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. · The Laboratory of Phytochemicals in Physiology, Department of Food Science, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. · Division of Endocrinology, Department of Medicine and Surgery, University of Parma, Parma, Italy. · Azienda Ospedaliera Universitaria of Parma, Parma, Italy. · Clinical Epidemiology Unit, Liver Research Center, Basovizza, Trieste, Italy. · Department of Food and Drug, University of Parma, Parma, Italy. · Department of Medicine and Surgery, Clinical Psychology Unit, University of Parma, Medical School Building, Parma, Italy. · Department of Medicine and Surgery, Building Clinica Medica Generale, University of Parma, Parma, Italy. · Laboratory of Probiogenomics, Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parma, Italy. · Department of Medicine and Surgery, Sport and Exercise Medicine Centre (SEM), University of Parma, Parma, Italy. · The Laboratory of Phytochemicals in Physiology, Department of Food and Drug, University of Parma, Medical School, Building A, Via Volturno 39, 43125, Parma, Italy. daniele.delrio@unipr.it. ·Acta Diabetol · Pubmed #29383587.

ABSTRACT: Most requests for authorization to bear health claims under Articles 13(5) and 14 related to blood glucose and insulin concentration/regulation presented to the European Food Safety Authority (EFSA) receive a negative opinion. Reasons for such decisions are mainly ascribable to poor substantiation of the claimed effects. In this scenario, a project was carried out aiming at critically analysing the outcome variables (OVs) and methods of measurement (MMs) to be used to substantiate health claims, with the final purpose to improve the quality of applications provided by stakeholders to EFSA. This manuscript provides a position statement of the experts involved in the project, reporting the results of an investigation aimed to collect, collate and critically analyse the information relevant to claimed effects (CEs), OVs and MMs related to blood glucose and insulin levels and homoeostasis compliant with Regulation 1924/2006. The critical analysis of OVs and MMs was performed with the aid of the pertinent scientific literature and was aimed at defining their appropriateness (alone or in combination with others) to support a specific CE. The results can be used to properly select OVs and MMs in a randomized controlled trial, for an effective substantiation of the claims, using the reference method(s) whenever available. Moreover, results can help EFSA in updating the guidance for the scientific requirements of health claims.

22 Guideline Diabetic Foot Australia guideline on footwear for people with diabetes. 2018

van Netten, Jaap J / Lazzarini, Peter A / Armstrong, David G / Bus, Sicco A / Fitridge, Robert / Harding, Keith / Kinnear, Ewan / Malone, Matthew / Menz, Hylton B / Perrin, Byron M / Postema, Klaas / Prentice, Jenny / Schott, Karl-Heinz / Wraight, Paul R. ·1School of Clinical Sciences, Queensland University of Technology, Brisbane, QLD Australia · 0000000089150953 · grid 1024 7 · Diabetic Foot Australia, Brisbane, QLD Australia · Wound Management Innovation Cooperative Research Centre, Brisbane, QLD Australia · Allied Health Research Collaborative, Metro North Hospital & Health Service, Brisbane, QLD Australia · 5Southern Arizona Limb Salvage Alliance (SALSA), Department of Surgery, University of Arizona College of Medicine, Tucson, AZ USA · 0000 0001 2168 186X · grid 134563 6 · Department of Rehabilitation, Academic Medical Center, University of Amsterdam, Amsterdam Movement Sciences, Amsterdam, the Netherlands · 7Vascular Surgery, The University of Adelaide, Adelaide, South Australia Australia · 0000 0004 1936 7304 · grid 1010 0 · 8University Dean of Clinical Innovation, Professor of Wound Healing Research, Cardiff University, Cardiff, UK · 0000 0001 0807 5670 · grid 5600 3 · 9High Risk Foot Service, Liverpool Hospital, South Western Sydney Local Health District, Sydney, NSW Australia · 0000 0001 2105 7653 · grid 410692 8 · 10Discipline of Podiatry, School of Allied Health, College of Science, Health and Engineering, La Trobe University, Bundoora, VIC Australia · 0000 0001 2342 0938 · grid 1018 8 · 11La Trobe Rural Health School, College of Science, Health and Engineering, La Trobe University, Bendigo, VIC Australia · Department of Rehabilitation Medicine, University of Groningen, University Medical Center Groningen, Department of Rehabilitation Medicine, Groningen, the Netherlands · Wound Consultant, Trojan Health, Perth, WA Australia · 14School of Health and Human Sciences (Pedorthics) Southern Cross University Gold Coast Campus, Bilinga, QLD Australia · 0000000121532610 · grid 1031 3 · 15Diabetic Foot Unit, Royal Melbourne Hospital, Melbourne, VIC Australia · 0000 0004 0624 1200 · grid 416153 4 ·J Foot Ankle Res · Pubmed #29371890.

ABSTRACT: Background: The aim of this paper was to create an updated Australian guideline on footwear for people with diabetes. Methods: We reviewed new footwear publications, (inter)national guidelines, and consensus expert opinion alongside the 2013 Australian footwear guideline to formulate updated recommendations. Result: We recommend health professionals managing people with diabetes should: (1) Advise people with diabetes to wear footwear that fits, protects and accommodates the shape of their feet. (2) Advise people with diabetes to always wear socks within their footwear, in order to reduce shear and friction. (3) Educate people with diabetes, their relatives and caregivers on the importance of wearing appropriate footwear to prevent foot ulceration. (4) Instruct people with diabetes at intermediate- or high-risk of foot ulceration to obtain footwear from an appropriately trained professional to ensure it fits, protects and accommodates the shape of their feet. (5) Motivate people with diabetes at intermediate- or high-risk of foot ulceration to wear their footwear at all times, both indoors and outdoors. (6) Motivate people with diabetes at intermediate- or high-risk of foot ulceration (or their relatives and caregivers) to check their footwear, each time before wearing, to ensure that there are no foreign objects in, or penetrating, the footwear; and check their feet, each time their footwear is removed, to ensure there are no signs of abnormal pressure, trauma or ulceration. (7) For people with a foot deformity or pre-ulcerative lesion, consider prescribing medical grade footwear, which may include custom-made in-shoe orthoses or insoles. (8) For people with a healed plantar foot ulcer, prescribe medical grade footwear with custom-made in-shoe orthoses or insoles with a demonstrated plantar pressure relieving effect at high-risk areas. (9) Review prescribed footwear every three months to ensure it still fits adequately, protects, and supports the foot. (10) For people with a plantar diabetic foot ulcer, footwear is not specifically recommended for treatment; prescribe appropriate offloading devices to heal these ulcers. Conclusions: This guideline contains 10 key recommendations to guide health professionals in selecting the most appropriate footwear to meet the specific foot risk needs of an individual with diabetes.

23 Guideline ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. 2018

Anonymous4830934. · ·Obstet Gynecol · Pubmed #29370047.

ABSTRACT: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

24 Guideline ACOG Practice Bulletin No. 190 Summary: Gestational Diabetes Mellitus. 2018

Anonymous4800934. · ·Obstet Gynecol · Pubmed #29370044.

ABSTRACT: Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. However, debate continues to surround the diagnosis and treatment of GDM despite several recent large-scale studies addressing these issues. The purposes of this document are the following: 1) provide a brief overview of the understanding of GDM, 2) review management guidelines that have been validated by appropriately conducted clinical research, and 3) identify gaps in current knowledge toward which future research can be directed.

25 Guideline 2018 AAHA Diabetes Management Guidelines for Dogs and Cats. 2018

Behrend, Ellen / Holford, Amy / Lathan, Patty / Rucinsky, Renee / Schulman, Rhonda. ·From the Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama (E.B.) · Department of Small Animal Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee (A.H.) · Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Starkville, Mississippi (P.L.) · Mid Atlantic Cat Hospital, Queenstown, Maryland (R.R.) · and Animal Specialty Group, Los Angeles, California (R.S.). ·J Am Anim Hosp Assoc · Pubmed #29314873.

ABSTRACT: Diabetes mellitus (DM) is a common disease encountered in canine and feline medicine. The 2018 AAHA Diabetes Management Guidelines for Dogs and Cats revise and update earlier guidelines published in 2010. The 2018 guidelines retain much of the information in the earlier guidelines that continues to be applicable in clinical practice, along with new information that represents current expert opinion on controlling DM. An essential aspect of successful DM management is to ensure that the owner of a diabetic dog or cat is capable of administering insulin, recognizing the clinical signs of inadequately managed DM, and monitoring blood glucose levels at home, although this is ideal but not mandatory; all topics that are reviewed in the guidelines. Insulin therapy is the mainstay of treatment for clinical DM. The guidelines provide recommendations for using each insulin formulation currently available for use in dogs and cats, the choice of which is generally based on efficacy and duration of effect in the respective species. Also discussed are non-insulin therapeutic medications and dietary management. These treatment modalities, along with insulin therapy, give the practitioner an assortment of options for decreasing the clinical signs of DM while avoiding hypoglycemia, the two conditions that represent the definition of a controlled diabetic. The guidelines review identifying and monitoring patients at risk for developing DM, which are important for avoiding unnecessary insulin therapy in patients with transient hyperglycemia or mildly elevated blood glucose.

Next